Literature DB >> 17230411

Hepatitis C virus coinfection and superinfection.

Jason T Blackard1, Kenneth E Sherman.   

Abstract

A hallmark of RNA viruses is their extreme genetic diversity. Within an individual, the hepatitis C virus (HCV) exists as a population of distinct but closely related viral variants, termed the "viral quasispecies." These variants may display divergent replicative capacity, cell tropism, immunologic escape, and antiviral-drug resistance. Coinfection with 2 or more distinct HCVs has been frequently documented. Moreover, several cases of HCV superinfection have been reported recently. However, few data are available regarding the clinical consequences of coinfection and superinfection, although these phenomena have important implications for HCV vaccine design and development, as well as for the efficacy of HCV therapeutic agents.

Entities:  

Mesh:

Year:  2007        PMID: 17230411     DOI: 10.1086/510858

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era.

Authors:  O Falade-Nwulia; M S Sulkowski; A Merkow; C Latkin; S H Mehta
Journal:  J Viral Hepat       Date:  2018-03       Impact factor: 3.728

Review 2.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

Review 3.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

4.  Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.

Authors:  Jason Grebely; Son Truong Pham; Gail V Matthews; Kathy Petoumenos; Rowena A Bull; Barbara Yeung; William Rawlinson; John Kaldor; Andrew Lloyd; Margaret Hellard; Gregory J Dore; Peter A White
Journal:  Hepatology       Date:  2012-02-29       Impact factor: 17.425

5.  Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b.

Authors:  Jayna Raghwani; Xiomara V Thomas; Sylvie M Koekkoek; Janke Schinkel; Richard Molenkamp; Thijs J van de Laar; Yutaka Takebe; Yasuhito Tanaka; Masashi Mizokami; Andrew Rambaut; Oliver G Pybus
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

Review 6.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

7.  Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis.

Authors:  Brian Webster; Silke Wissing; Eva Herker; Melanie Ott; Warner C Greene
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Independence of Anaplasma marginale strains with high and low transmission efficiencies in the tick vector following simultaneous acquisition by feeding on a superinfected mammalian reservoir host.

Authors:  Maria F B M Galletti; Massaro W Ueti; Donald P Knowles; Kelly A Brayton; Guy H Palmer
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

Review 9.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 10.  Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.

Authors:  Nick Scott; Margaret Hellard; Emma Sue McBryde
Journal:  Virulence       Date:  2015-08-25       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.